MNPR Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Monopar Therapeutics's net margin of 12.11%. Monopar Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

Monopar Therapeutics has a consensus price target of $45.67, signalling upside risk potential of 47.79%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 46.83%. Given that Monopar Therapeutics has higher upside potential than Electromed, analysts believe Monopar Therapeutics is more attractive than Electromed.

Monopar Therapeutics has a beta of 1.181, which suggesting that the stock is 18.062% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Monopar Therapeutics's net income of -$1.3M is lower than Electromed's net income of $2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 33.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 3.78x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Monopar Therapeutics's net margin of -2.16%. Monopar Therapeutics's return on equity of -- beat Myomo's return on equity of -48.64%.

Monopar Therapeutics has a consensus price target of $45.67, signalling upside risk potential of 47.79%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 62.98%. Given that Myomo has higher upside potential than Monopar Therapeutics, analysts believe Myomo is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.181, which suggesting that the stock is 18.062% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Myomo quarterly revenues of $12.1M. Monopar Therapeutics's net income of -$1.3M is lower than Myomo's net income of -$260.1K. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 6.30x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Monopar Therapeutics's net margin of -1226.82%. Monopar Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Monopar Therapeutics has a consensus price target of $45.67, signalling upside risk potential of 47.79%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 496%. Given that VolitionRX has higher upside potential than Monopar Therapeutics, analysts believe VolitionRX is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.181, which suggesting that the stock is 18.062% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Monopar Therapeutics's net income of -$1.3M is higher than VolitionRX's net income of -$5.8M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 36.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Monopar Therapeutics's net margin of -10.04%. Monopar Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Monopar Therapeutics has a consensus price target of $45.67, signalling upside risk potential of 47.79%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 259.34%. Given that Xtant Medical Holdings has higher upside potential than Monopar Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.181, which suggesting that the stock is 18.062% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Monopar Therapeutics's net income of -$1.3M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.56x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.